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Abstract 
The levels of soluble intercellular adhesion molecule-1 (sICAM-1) have been reported to increase in patients with idi-
opathic pulmonary fibrosis. However, the utility of sICAM-1 has not been reported in detail. The aim of this study was 
to investigate whether sICAM-1 was a useful biomarker for stable idiopathic pulmonary fibrosis (IPF) and early phase 
of acute exacerbation of IPF. The patients who were diagnosed with IPF between 2013 and 2015 were enrolled. The 
levels of sICAM-1 and other interstitial pneumonia markers were measured. In this study, 30 patients with stable IPF 
and 11 patients with acute exacerbation of IPF were collected. Mean sICAM-1 levels were 434 ± 139 ng/mL for the 
stable phase of IPF, 645 ± 247 ng/mL for early phase of acute exacerbation of IPF, 534 ± 223 ng/mL for connective tis-
sue disease-associated interstitial pneumonia, 221 ± 42 for chronic obstructive pulmonary disease, and 150 ± 32 ng/
mL in healthy volunteers. For the stable phase of IPF, sICAM-1 levels correlated with Krebs von den Lungen-6 (KL-6) 
(r value: 0.41; p value: 0.036). Mean sICAM-1 levels were significantly higher in patients with early phase of acute 
exacerbation of IPF than with stable phase of IPF (p = 0.0199). Multiple logistic analyses indicated that the predictors 
for early phase of acute exacerbation of IPF were only sICAM-1 and C-reactive protein (odds ratio: 1.0093; 1.6069). In 
patients with stable IPF, sICAM-1 levels correlated with KL-6; sICAM-1 might be a predictive indicator for prognosis. In 
the early phase of acute exacerbation of IPF, sICAM-1 might be more useful for diagnosis than other interstitial pneu-
monia markers.
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Background
Intercellular adhesion molecule-1 (ICAM-1) is a glyco-
protein with a molecular weight of 80–110 kD belong-
ing to the immunoglobulin superfamily. Stimulation of 
inflammatory cytokines such as interferon and inter-
leukin (IL)-1 leads to expression of ICAM-1 in vascular 
endothelial cells, tracheal epithelial cells, and fibroblasts 
within a few hours (Munro et  al. 1989; Hubbard and 
Rothlein 2000; Vogetseder et al. 1989). As the expressed 
ICAM-1 is involved in adhesion to white blood cells 
(WBCs), it is considered to be a protein involved early 
in the immune response (Albelda et  al. 1994). As some 
of the expressed ICAM-1 is released into the circulat-
ing blood, measurement of soluble ICAM-1 (sICAM-1) 
levels in blood makes it possible to estimate ICAM-1 
expression in the tissue.
For example, sICAM-1 levels have been reported to be 
increased in many inflammatory diseases such as infec-
tions, autoimmune diseases, and allergic diseases (Greve 
et al. 1989; Davies et al. 1992; Wegner et al. 1990). Fur-
thermore, sICAM-1 levels have been reported to increase 
in pulmonary diseases, including chronic obstructive 
pulmonary disease (COPD), idiopathic pulmonary fibro-
sis (IPF), and connective tissue disease-associated inter-
stitial pneumonia (CTD-associated IP) (Risse et al. 1994; 
Richards et  al. 2012; Hasegawa et  al. 2014). Few studies 
have compared sICAM-1 levels in different pulmonary 
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diseases. Although Krebs von den Lungen-6 (KL-6) and 
surfactant protein D (SP-D) are used clinically in Japan 
as prognostic markers for IPF (Yokoyama et  al. 2006; 
Takahashi et al. 2000), few studies have investigated the 
relationship between these and sICAM-1 in patients with 
IPF. We investigated these questions in this study.
Acute exacerbation of IPF is a disease with a poor 
prognosis in which new ground-glass opacities and infil-
trates in both lungs and rapid respiratory failure appear 
in patients with chronic IPF (Kondoh et  al. 1993). The 
Japanese guidelines state that blood KL-6, SP-D, C-reac-
tive protein (CRP), and lactate dehydrogenase (LDH) 
are reference markers for acute exacerbation of IPF. As 
sICAM-1 levels increase in the early stages of inflamma-
tion, we estimated that sICAM-1 could become a bio-
marker for early phase of acute exacerbation of IPF.
Methods
Subjects
The patients who were diagnosed with IPF, CTD-asso-
ciated IP, and COPD at Saitama Red Cross Hospital 
between July 2013 and July 2015 were enrolled in this 
study. IPF was diagnosed according to the following cri-
teria: The patient was 50  years or older and conformed 
with the 2011 American Thoracic Society/European Res-
piratory Society IPF statement (Raghu et al. 2011); high-
resolution computed tomography (CT) images usually 
showed usual interstitial pneumonia (UIP) or possible 
UIP, and UIP caused by collagen disease, hypersensitivity 
pneumonitis, or drug-induced pneumonia was clinically 
excluded. For CTD-associated IP, two collagen disease 
specialists and two respiratory disease specialists at 
Saitama Red Cross Hospital had diagnosed CTD-associ-
ated IP based on physical findings, blood tests, and high-
resolution CT images.
“Stable IPF” was defined as patients with IPF who are 
stable for 2 months before the examination. In stable IPF, 
sICAM-1, KL-6 (reference range 0–500 U/mL), SP-D 
(reference range 0–110  ng/mL), CRP (reference range 
0–0.5 mg/dL), LDH (reference range 119–229 UI/L), and 
WBCs (reference range 3100–8800/μL) were measured. 
Similarly, sICAM-1 was measured in healthy volunteers 
and patients with CTD-associated IP and COPD.
The diagnosis of acute exacerbation of IPF was based 
on the Japanese guidelines. Hence, after excluding 
other diseases such as obvious infections or heart fail-
ure, acute exacerbation of IPF was diagnosed based on 
the presence of all of the following: Increased severity 
of dyspnea, high-resolution CT findings showed hon-
eycomb lung and new ground-glass appearances and 
infiltrates, and a decrease in partial pressure of oxygen 
in arterial blood of 10  mmHg or greater. On the day 
when acute exacerbation of IPF was diagnosed, blood 
sICAM-1, KL-6, SP-D, et  al. were measured. Patients 
for which blood was collected on the first day of acute 
exacerbation of IPF were defined as “AEx IPF”. Almost 
AEx IPF cases underwent repeat measurements of 
sICAM-1 levels in the stable phase before or after acute 
exacerbation of IPF. All the blood samples in this study 
were centrifuged after clot formation. The serum sam-
ples were stored at −20  °C prior to analysis. Serum 
levels of ICAM-1 were measured by enzyme-linked 
immunosorbent assay (SRL Inc., Tokyo, Japan). This 
study was approved by the institutional review board of 
the Saitama Red Cross Hospital. Written consent was 
received from all patients.
Immunohistochemical and immunofluorescence staining
Lung tissue samples were taken during surgery or 
autopsy performed at Saitama Red Cross Hospital in the 
past. Non-cancerous lung tissue samples were selected 
(two cases in each group) from patients of lung cancer 
with stable IPF, CTD-associated IP, and COPD receiving 
lung surgery. Autopsy lung tissue samples from AEx IPF 
cases (two cases) were used. AEx IPF and COPD lung tis-
sue was taken from patients different from those in which 
serum sICAM-1 levels were measured. Resected tissue 
was embedded in paraffin after immersion fixation for 
4 h in 10 % formalin. Lung tissue was cut into 3 μm-thick 
slices. The use of the tissue samples was approved by the 
ethical review board of our hospital.
Lung tissue underwent immunohistochemical staining 
using a fully automated immunohistochemical stainer 
(Ventana BenchMark GX, Ultra View DAB: Roche 
Diagnostics International Ltd., Tokyo, Japan). For anti-
gen activation, specimens underwent heat processing 
(95–100  °C) for 60  min in ethylenediaminetetraacetic 
acid buffer solution (pH 8.5) and we used rabbit poly-
clonal antibody against intracellular adhesion molecule-1 
(Santa Cruz Biotechnology INC., Texas, the USA: 1:4000 
dilution) as the primary antibody. For the horseradish 
peroxidase reaction chromogenic substrate, 3,3′-diamin-
obenzidine and compared nuclear staining with hema-
toxylin were used.
Lung tissue also underwent manual immunofluores-
cence staining. Paraffin-embedded lung tissue was depar-
affinized, hydrated and autoclaved in citrate acid buffer 
(pH 6.0, 121 °C for 15 min). Bovine serum albumin (3 %) 
was used to block non-specific hydrophobic binding for 
30  min and we used rabbit polyclonal antibody against 
ICAM-1 (1:400 dilution) as the primary antibody for 1 h. 
Secondary antibody with Alexa Flour 488-conjugated 
anti-rabbit IgG (Abcam Plc., Cambridge, UK) and coun-
terstain with DAPI were used.
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Statistical analysis
The unpaired t test was used for comparisons between 
two groups. To investigate the correlation between 
sICAM-1 and other interstitial pneumonia markers, 
Spearman’s rank correlation coefficient was used. Items 
suspected to be related to early acute exacerbation 
(sICAM-1, KL-6, SP-D, LDH, CRP, and WBC) were eval-
uated using univariate and multivariate logistic regres-
sion analyses. The analysis was performed with the Excel 
Statistics software (SSRI Co., Ltd.).
Results
For the 30 patients with stable IPF, mean percentage 
forced expiratory vital capacity (%FVC) was 78.4  % 
and percentage diffusing capacity of the lungs for car-
bon monoxide (%DLco) was 74.9  %, indicating many 
patients with mild IPF (Table  1). There were seven 
patients with CTD-associated IP, six patients with 
COPD, and seven healthy volunteers. Mean sICAM-1 
levels were 432 ± 139 ng/mL for stable IPF, 534 ± 223 
for CTD-associated IP, 221 ± 42 ng/mL for COPD and 
150 ± 32 ng/mL for healthy volunteers. Thus, sICAM-1 
levels were significantly higher in patients with COPD 
than in healthy volunteers. In patients with stable IPF 
and CTD-associated IP, sICAM-1 levels were sig-
nificantly higher than those in healthy volunteers and 
patients with COPD (Fig.  1). Investigation of possible 
correlations between biomarkers in patients with sta-
ble IPF indicated that sICAM-1 levels exhibited a posi-
tive correlation with KL-6 and CRP (r value 0.41; 0.36) 
(Table 2).
Among the 11 patients with AEx IPF, mean sICAM-1 
levels were 645 ± 247. Mean sICAM-1 levels were sig-
nificantly higher in cases with AEx IPF than with stable 
IPF (p = 0.0199) (Fig. 2). Investigation of possible cor-
relations between biomarkers in patients with AEx IPF 
indicated that sICAM-1 levels exhibited a positive cor-
relation with only KL-6 (r value 0.82) (Table 3). Com-
parison of biomarkers in cases with AEx IPF and stable 
IPF indicated that independent predictors for early 
Table 1 Characteristics of study population
Data are presented as n or mean ± standard deviation, unless otherwise stated. The unpaired t test was used (versus stable IPF)
IPF idiopathic pulmonary fibrosis, CTD-associtated IP connective tissue disease-associated interstitial pneumonia, COPD chronic obstructive pulmonary disease, N/A 
not available, KL-6 Krebs von den Lungen-6, SP-D surfactant protein D, WBC white blood cell, LDH lactate dehydrogenase, CRP C-reactive protein, VC vital capacity, % 
pred  % predicted, FVC forced vital capacity, DLco diffusion capacity of the lung for carbon monoxide
* p < 0.05, ** p < 0.01
Characteristics Stable IPF CTD-associated IP COPD Healthy volunteer
Subjects 30 7 6 7
 Male/female 25/5 3/4* 6/0 1/6**
Age (years) 72.3 ± 6.3 73.3 ± 6.8 75.5 ± 6.5 26.9 ± 4.0**
Smoking history
 Never/Ex- and current 7/23 3/4 0/6 6/1**
Treatment received
 None 12 0 N/A N/A
 N-acetylcysteine 9 0 N/A N/A
 Pirfenidone 2 0 N/A N/A
 Steroids 3 0 N/A N/A
 Steroids + immunosuppressant 3 5 N/A N/A
 Steroids + Pirfenidone 1 2 N/A N/A
Blood tests
 KL-6 (U/mL) 1174 ± 1008 951 ± 544 N/A N/A
 SP-D (ng/mL) 240 ± 131 218 ± 215 N/A N/A
 WBC (/μL) 7660 ± 2290 11000 ± 2290** 9270 ± 2990 N/A
 LDH (IU/L) 233 ± 58 246 ± 55 173 ± 34* N/A
 CRP (mg/dL) 1.00 ± 2.49 2.00 ± 2.87 0.8 ± 1.08 N/A
Pulmonary function
 VC  % pred (%) 78.6 ± 23.4 75.5 ± 14.6 74.5 ± 13.9 N/A
 FVC  % pred (%) 78.4 ± 23.1 74.1 ± 16.2 70.0 ± 11.3 N/A
 FEV1 % pred (%) 99.8 ± 28.1 86.7 ± 26.7 38.9 ± 11.7** N/A
 FEV1/FVC (%) 88.1 ± 6.2 80.0 ± 11.4 37.8 ± 8.1** N/A
 DLco % pred (%) 74.9 ± 28.9 56.7 ± 19.0 94.1 ± 34.5 N/A
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phase of acute exacerbation of IPF were sICAM-1 and 
CRP (Table  4). The optimal sICAM-1 cutoff for AEx 
IPF and stable IPF cases was found to be 535 ng/mL by 
receiver operating characteristic curve analysis (Fig. 3).
Lung histopathology
ICAM-1 in lung tissue was investigated using immu-
nohistochemical and immunofluorescence staining. In 
healthy tissue, ICAM-1 was rarely expressed; however, in 
patients with stable IPF, ICAM-1 was observed, particu-
larly, in the epithelial cells of cysts and bronchiectasis. 
ICAM-1 was also observed in some vascular endothe-
lial cells. In cases with CTD-associated IP and AEx IPF, 
ICAM-1 expression was even stronger than that observed 
in cases with stable IPF (Figs. 4, 5).
Discussion
This study demonstrated that sICAM-1 levels were 
increased in patients with stable IPF and that a positive 
correlation existed between sICAM-1 and KL-6. This 
study also indicated that sICAM-1 levels were more use-
ful than KL-6 or SP-D for diagnosing the early phase of 
acute exacerbation of IPF.
It has previously been reported that sICAM-1 levels 
are elevated in diseases other than IPF (Greve et al. 1989; 
Davies et al. 1992; Wegner et al. 1990), and sICAM-1 lev-
els were thought to have little disease specificity to IPF. 
Few studies have compared sICAM-1 levels in patients 
with IPF and COPD. In this study, sICAM-1 levels were 
significantly higher in cases with stable IPF and CTD-
associated IP than in cases with COPD. When compared 
to previous reports on IPF (Takehara et al. 2001; Tsout-
sou et al. 2004) and COPD (Oelsner et al. 2013) related 
to sICAM-1, sICAM-1 levels were higher in patients with 
IPF than COPD. Differences in ICAM-1 expression in 
lung tissue were also observed between patients with IPF 
and COPD in this study, which was consistent with the 
biomarker results.
Few studies have compared sICAM-1 levels with 
other interstitial pneumonia markers such as KL-6. In 
this study, sICAM-1 levels correlated with KL-6 in the 
stable phase. As KL-6 is a strong prognostic marker of 
IPF (Yokoyama et  al. 2006), sICAM-1 levels might be 
a useful prognostic indicator. A previous study also 
reported that sICAM-1 levels could be a prognostic 
marker of IPF (Richards et  al. 2012). Meanwhile, no 
correlation was observed between sICAM-1 and SP-D. 
The phenomenon of dissociation of KL-6 and SP-D 
has previously been indicated. It has been reported 
that KL-6 tends to strongly reflect honeycomb lung 
features, whereas SP-D reflects ground-glass opaci-
ties on high-resolution CT (Takahashi et  al. 2000). In 
this study, immunohistochemical staining of stable 
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Fig. 1 Levels of sICAM-1 in healthy volunteers and patients with 
Stable IPF, CTD-associated IP, and COPD. Black lines represent the aver-
age values. The unpaired t test was used. sICAM-1 soluble intercellular 
adhesion molecule-1, IPF idiopathic pulmonary fibrosis, CTD-associ-
ated IP connective tissue disease-associated interstitial pneumonia, 
COPD chronic obstructive pulmonary disease
Table 2 Correlations between  sICAM-1 and  other param-
eters in patients with stable IPF
Spearman’s rank correlation coefficient was used
sICAM-1 soluble intercellular adhesion molecule-1, IPF idiopathic pulmonary 
fibrosis, KL-6 Krebs von den Lungen-6, SP-D surfactant protein D, LDH lactate 
dehydrogenase, CRP C-reactive protein, FVC forced vital capacity, % pred % 
predicted, DLco diffusion capacity of the lung for carbon monoxide





FVC % pred 0.25 −0.22
DLco % pred 0.18 −0.27






















































(p = 0.045) (p = 0.001)(n.s.)
(p = 0.002)
Fig. 2 Levels of biomarkers in patients with Stable IPF and AEx IPF. The unpaired t test was used. sICAM-1 soluble intercellular adhesion molecule-1, 
KL-6 Krebs von den Lungen-6, SP-D surfactant protein D, CRP C-reactive protein, LDH lactate dehydrogenase, WBC white blood cell
Table 3 Correlations between  sICAM-1 and  other param-
eters in  patients with  early phase of  acute exacerbation 
of IPF
Spearman’s rank correlation coefficient was used
sICAM-1 soluble intercellular adhesion molecule-1, IPF idiopathic pulmonary 
fibrosis, KL-6 Krebs von den Lungen-6, SP-D surfactant protein D, LDH lactate 
dehydrogenase, CRP C-reactive protein, WBC white blood cell






Table 4 Risk factors of  early phase of  acute exacerbation 
of IPF
IPF idiopathic pulmonary fibrosis, CI confidence interval, sICAM-1 soluble 
intercellular adhesion molecule-1, KL-6 Krebs von den Lungen-6, SP-D surfactant 
protein D, LDH lactate dehydrogenase, CRP C-reactive protein, WBC white blood 
cell
Parameters p value Odd ratio 95 % CI
Univariate regression analysis
 sICAM-1 0.007 1.0062 1.0017–1.0107
 KL-6 0.114 1.0004 0.9999–1.0010
 SP-D 0.008 1.0079 1.0020–1.0137
 LDH 0.024 1.0120 1.0016–1.0225
 CRP 0.015 1.2831 1.0459–1.5696
 WBC 0.006 1.0005 1.0001–1.0009
Multivariate logistic regression analysis
 sICAM-1 0.028 1.0093 1.0010–1.0176
 CRP 0.009 1.6069 1.1248–2.2957
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staining in the honeycomb lung or epithelial cells of 
bronchiectasis than in interstitial cells. Thus, sICAM-1 
levels appear to be a biomarker that is more similar to 
KL-6 than SP-D.
Acute exacerbation of IPF, which occurs in approxi-
mately 5–15  % of cases with stable IPF per year, has a 
poor prognosis with a mortality rate of 50–80  % (Song 
et al. 2011). Early diagnosis is therefore considered cru-
cial. KL-6 has been widely investigated in the markers of 
acute exacerbation of IPF (Zhang and Kaminski 2012). It 
has been reported that KL-6 levels rise in patients with 
acute exacerbation of IPF (Collard et  al. 2010; Ishikawa 
et al. 2012). On the other hand, KL-6 levels do not always 
rise in the early phase of acute exacerbation of IPF (Ishi-
zaka et  al. 2004; Kakugawa et  al. 2013). In this study, 
sICAM-1 levels were elevated already on the first day 
diagnosed as acute exacerbation of IPF, suggesting that 
it could be a biomarker for early phase of acute exacer-
bation of IPF. Because the expression of ICAM-1 was 
enhanced in the initial phase of inflammation and early 
phase of acute respiratory distress syndrome (Schütte 
et  al. 1996; Pugin et  al. 1996; Kuppner et  al. 1990), 
sICAM-1 levels may also rise in the early phase of acute 
exacerbation of IPF.
The limitations of this study include the fact that 
prognosis could not be investigated due to the small 
sample size. A previous report demonstrated that 
sICAM-1 levels were a prognostic factor for IPF (Risse 
et  al. 1994). Hence, verification with large samples of 
IPF and CTD-associated IP cases is required. Further-
more, the tissue samples used for acute exacerbation 
cases were from autopsy cases, and therefore, these 
were not tissue samples from the early phase of acute 
exacerbation. We also cannot rule out the influence of 
treatments such as steroid pulse therapy. Despite this, 
strong ICAM-1 staining in lung tissue was observed in 
cases with AEx IPF.
In conclusion, sICAM-1 levels in patients of stable IPF 
strongly correlated with KL-6; sICAM-1 might be a pre-
dictive indicator for prognosis. In the early phase of acute 
exacerbation of IPF, sICAM-1 might be more useful for 
diagnosis than other interstitial pneumonia markers. 























Fig. 3 Receiver operator characteristics curves for identification of 
patients with acute exacerbation of idiopathic pulmonary fibrosis. 
sICAM-1 soluble intercellular adhesion molecule-1, KL-6 Krebs von den 
Lungen-6, SP-D surfactant protein D
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Fig. 4 Immunohistochemical staining for ICAM-1 in the lung tissue. Contrast nuclear staining with hematoxylin was used. Stable IPF (a), AEx IPF (b), 
CTD-associated IP (c), COPD (d), normal lung (e). Original magnifications, ×10
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Fig. 5 Immunofluorescence staining for ICAM-1 (green). Contrast nuclear staining with DAPI (blue) was used. Stable IPF (a), AEx IPF (b), CTD-associ-
ated IP (c), COPD (d), normal lung (e). Arrowheads pointed to examples of ICAM-1. Original magnifications, ×40
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